72 related articles for article (PubMed ID: 20008547)
21. Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. III. Histopathology.
Camras CB; Friedman AH; Rodrigues MM; Tripathi BJ; Tripathi RC; Podos SM
Invest Ophthalmol Vis Sci; 1988 Sep; 29(9):1428-36. PubMed ID: 3166452
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats.
Marui A; Hirose K; Maruyama T; Arai Y; Huang Y; Doi K; Ikeda T; Komeda M
J Thorac Cardiovasc Surg; 2006 Mar; 131(3):587-93. PubMed ID: 16515909
[TBL] [Abstract][Full Text] [Related]
23. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Nov; 446():1-317. PubMed ID: 12594529
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of bone-bonding ability of bioactive titanium by prostaglandin E2 receptor selective agonist.
Onishi E; Fujibayashi S; Takemoto M; Neo M; Maruyama T; Kokubo T; Nakamura T
Biomaterials; 2008 Mar; 29(7):877-83. PubMed ID: 18045684
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats.
Tanaka M; Sakai A; Uchida S; Tanaka S; Nagashima M; Katayama T; Yamaguchi K; Nakamura T
Bone; 2004 Jun; 34(6):940-8. PubMed ID: 15193540
[TBL] [Abstract][Full Text] [Related]
26. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
27. NTP Toxicology and Carcinogenesis Studies of Triethanolamine (CAS No. 102-71-6) in F344 Rats and B6C3F1 Mice (Dermal Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Nov; 449():1-298. PubMed ID: 12594526
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
29. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Brandt JD; Beiser JA; Gordon MO; Kass MA;
Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
[TBL] [Abstract][Full Text] [Related]
30. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma.
Yanochko GM; Affolter T; Eighmy JJ; Evans MG; Khoh-Reiter S; Lee D; Miller PE; Shiue MH; Trajkovic D; Jessen BA
J Ocul Pharmacol Ther; 2014 Jun; 30(5):429-39. PubMed ID: 24720348
[TBL] [Abstract][Full Text] [Related]
31. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide.
Sakuma Y; Tanaka K; Suda M; Yasoda A; Natsui K; Tanaka I; Ushikubi F; Narumiya S; Segi E; Sugimoto Y; Ichikawa A; Nakao K
J Bone Miner Res; 2000 Feb; 15(2):218-27. PubMed ID: 10703923
[TBL] [Abstract][Full Text] [Related]
32. Pattern of ocular response to topical and systemic prostaglandin.
Green K; Kim K
Invest Ophthalmol; 1975 Jan; 14(1):36-40. PubMed ID: 1110134
[TBL] [Abstract][Full Text] [Related]
33. Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications.
Johnson TV; Toris CB; Fan S; Camras CB
J Glaucoma; 2008 Mar; 17(2):89-99. PubMed ID: 18344753
[TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory effects of topical supernatant from human amniotic membrane cell culture on canine deep corneal ulcer after human amniotic membrane transplantation.
Wichayacoop T; Briksawan P; Tuntivanich P; Yibchok-Anun S
Vet Ophthalmol; 2009; 12(1):28-35. PubMed ID: 19152595
[TBL] [Abstract][Full Text] [Related]
35. Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys.
Proksch JW; Lowe ER; Ward KW
Drug Metab Dispos; 2011 Jul; 39(7):1181-7. PubMed ID: 21441467
[TBL] [Abstract][Full Text] [Related]
36. Iloprost, a stable prostacyclin analog, reduces intraocular pressure.
Hoyng PF; de Jong N
Invest Ophthalmol Vis Sci; 1987 Mar; 28(3):470-6. PubMed ID: 2435669
[TBL] [Abstract][Full Text] [Related]
37. Ocular changes in beagle dogs following oral administration of CGS 24565, a potential hypolipidemic agent.
Schiavo DM; Bentley P
Toxicol Sci; 2000 May; 55(1):189-94. PubMed ID: 10788573
[TBL] [Abstract][Full Text] [Related]
38. Clinical progression of ocular injury following arsenical vesicant lewisite exposure.
Tewari-Singh N; Croutch CR; Tuttle R; Goswami DG; Kant R; Peters E; Culley T; Ammar DA; Enzenauer RW; Petrash JM; Casillas RP; Agarwal R
Cutan Ocul Toxicol; 2016 Dec; 35(4):319-28. PubMed ID: 27002633
[TBL] [Abstract][Full Text] [Related]
39. Ocular drug delivery nanowafer with enhanced therapeutic efficacy.
Yuan X; Marcano DC; Shin CS; Hua X; Isenhart LC; Pflugfelder SC; Acharya G
ACS Nano; 2015 Feb; 9(2):1749-58. PubMed ID: 25585134
[TBL] [Abstract][Full Text] [Related]
40. Barrier qualities of the mouse eye to topically applied drugs.
Wang Z; Do CW; Avila MY; Stone RA; Jacobson KA; Civan MM
Exp Eye Res; 2007 Jul; 85(1):105-12. PubMed ID: 17490649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
